Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00701675 · ClinicalTrials.gov registry record · Phase 4
Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT00701675: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT00701675 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00701675, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
Generalized anxiety disorder (GAD) is a very common disorder in the geriatric population with prevalence rates reaching 7% and even higher rates of 8% among elderly veterans. However, despite such high prevalence treating clinicians are presently forced to address treatment issues in this population without the guidance of scientific data. This proposal aims to begin to address this void. In light of emerging information regarding efficacy of the newer anti anxiety agents, specifically the selective serotonin reuptake inhibitors (SSRIs), in the treatment of young adult GAD patients it is time to prospectively evaluate the safety and efficacy of these medications in the treatment of elderly GAD patients. Therefore, this study will examine the effects and safety of the SSRI sertraline at different doses (50mg and 100mg per day) for older patients with GAD.
Interventions
- DRUG sertraline 50 mg daily
- DRUG sertraline 100 mg daily
- DRUG Placebo 50 or 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00701675
The ClinicalTrials.gov registry entry for NCT00701675 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sertraline 50 mg daily is the first listed.
NCT00701675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00701675 about?
NCT00701675 is a clinical study titled "Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly". Generalized anxiety disorder (GAD) is a very common disorder in the geriatric population with prevalence rates reaching 7% and even higher rates of 8% among elderly veterans. However, despite such high prevalence treating clinicians are presently forced to address treatment issues in this population...
What is the current status of trial NCT00701675?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2005-10. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00701675?
The interventions under investigation include: sertraline 50 mg daily (DRUG), sertraline 100 mg daily (DRUG), Placebo 50 or 100 mg (DRUG).
Who is sponsoring clinical trial NCT00701675?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.